{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:41:43Z","timestamp":1769604103162,"version":"3.49.0"},"reference-count":28,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"crossref","award":["APP1171781"],"award-info":[{"award-number":["APP1171781"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Uniting NSW ACT","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"St Vincent\u2019s Hospital","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,7,19]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Supervised injectable opioid treatment (SIOT) is an evidence-based intervention targeting opioid-dependent people for whom existing treatments have been ineffective. This project will primarily assess the feasibility and the acceptability of time-limited SIOT using injectable hydromorphone delivered in an existing Australian public opioid treatment programme, with secondary outcomes of safety, cost, changes in drug use and other health outcomes. If feasible, the goal is to scale up the intervention to be more widely available in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Between 20 and 30 participants will be offered two times per day hydromorphone to inject under direct observation, in addition to their current opioid agonist treatment (OAT), for up to 2 years. At the end of 2 years of supervised hydromorphone treatment, participants will be continued on standard OAT only. Informed consent will be obtained from all participants included in the study. This is a single-site, uncontrolled, open-label study where quantitative and qualitative interview data will be collected at baseline, 12 months and lastly at 3 months following their final hydromorphone dose. The main outcome measures are feasibility, as assessed by recruitment, retention and participation in treatment, and acceptability to participants, clinic staff and other stakeholders assessed by qualitative interviews. Secondary outcome measures of safety, as assessed by adverse events, and cost will also be assessed, as well as a range of other drug and health outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study received ethical approval from the St Vincent\u2019s Hospital Human Research Ethics Committee (2019\/ETH00418). This will be the first study of time-limited SIOT in the Australian setting. All results will be submitted to peer-reviewed journals, scientific conferences and local practice meetings. A preliminary report on outcomes will also be presented to local health policy makers. A consumer and community forum will also be held to feedback results to a broader audience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12621001729819.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-082553","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T13:01:56Z","timestamp":1722690116000},"page":"e082553","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Implementation of time-limited parenteral hydromorphone in people with treatment-resistant injecting opioid use disorder: a protocol for a single-site, uncontrolled, open-label study to assess feasibility, safety and cost"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1777-2941","authenticated-orcid":false,"given":"Craig","family":"Rodgers","sequence":"first","affiliation":[{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-3325","authenticated-orcid":false,"given":"Krista J","family":"Siefried","sequence":"additional","affiliation":[{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"},{"name":"University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Ritter","sequence":"additional","affiliation":[{"name":"Drug Policy Modelling Program, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vendula","family":"Belackova","sequence":"additional","affiliation":[{"name":"Uniting MSIC, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8230-0386","authenticated-orcid":false,"given":"Carla","family":"Treloar","sequence":"additional","affiliation":[{"name":"University of South Wales, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Jauncey","sequence":"additional","affiliation":[{"name":"Uniting MSIC, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-8305","authenticated-orcid":false,"given":"Nadine","family":"Ezard","sequence":"additional","affiliation":[{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"},{"name":"University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren","family":"Roberts","sequence":"additional","affiliation":[{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Steele","sequence":"additional","affiliation":[{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem","family":"van den Brink","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Strang","sequence":"additional","affiliation":[{"name":"Addictions, Kings College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Oviedo-Joekes","sequence":"additional","affiliation":[{"name":"University of British Columbia Centre for Health Evaluation, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[{"name":"Discipline of Addiction Medicine, University of Sydney, Surry Hills, New South Wales, Australia"},{"name":"The Langton Centre, South East Sydney Local Health District, Surry Hills, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian John","family":"Dunlop","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Clinical Services Research, Hunter New England Health, Newcastle, New South Wales, Australia"},{"name":"The University of Newcastle Hunter Medical Research Institute, New Lambton, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Bell","sequence":"additional","affiliation":[{"name":"University of New South Wales, Sydney, New South Wales, Australia"},{"name":"King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"2025121605195859000_14.8.e082553.1","first-page":"10","article-title":"Treatment of patients with opioid dependence","volume":"16","author":"Lintzeris","year":"2015","journal-title":"Med Today"},{"key":"2025121605195859000_14.8.e082553.2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923060-00002"},{"key":"2025121605195859000_14.8.e082553.3","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.190344"},{"key":"2025121605195859000_14.8.e082553.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1277"},{"key":"2025121605195859000_14.8.e082553.5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.5694\/j.1326-5377.1996.tb122243.x","article-title":"The ACT heroin trial proposal: an overview","volume":"164","author":"Bammer","year":"1996","journal-title":"Med J Aust"},{"key":"2025121605195859000_14.8.e082553.6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5694\/j.1326-5377.2002.tb04289.x","article-title":"Breaking the deadlock over an australian trial of injectable opioid maintenance","volume":"176","author":"Hall","year":"2002","journal-title":"Med J Aust"},{"key":"2025121605195859000_14.8.e082553.7","first-page":"1339","article-title":"Supervised injectable opioid treatment for the management of opioid dependence","volume":"78","author":"Bell","year":"2018","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025121605195859000_14.8.e082553.8","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.114.149195"},{"key":"2025121605195859000_14.8.e082553.9","unstructured":"Addiction EMCfDaD . New heroin-assisted treatment: recent evidence and current practices of supervised injectable heroin treatment in Europe and Beyond. Luxembourg: Publications Office of the European Union, 2012."},{"key":"2025121605195859000_14.8.e082553.10","doi-asserted-by":"crossref","DOI":"10.1186\/1747-597X-10-3","article-title":"The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency","volume":"10","author":"Oviedo-Joekes","year":"2015","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2025121605195859000_14.8.e082553.11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/0706743716673966","article-title":"Supervised injectable heroin: A clinical perspective","volume":"62","author":"Bell","year":"2017","journal-title":"Can J Psychiatry"},{"key":"2025121605195859000_14.8.e082553.12","unstructured":"Strang J , Groshkova T , Metrebian N , et al . New heroin-assisted treatment: recent evidence and current practices of supervised injectable heroin treatment in europe and beyond: EMCDDA. 2012."},{"key":"2025121605195859000_14.8.e082553.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02754.x"},{"key":"2025121605195859000_14.8.e082553.14","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2010.540624"},{"key":"2025121605195859000_14.8.e082553.15","unstructured":"World Health Organization . The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. geneva. 1993."},{"key":"2025121605195859000_14.8.e082553.16","unstructured":"Tsoris A , Marlar CA . Use of the child pugh score in liver disease. Treasure Island, FL: StatPearls Publishing, 2022."},{"key":"2025121605195859000_14.8.e082553.17","doi-asserted-by":"crossref","DOI":"10.1136\/sbmj.j1821","article-title":"How to approach the mental state examination","volume":"357","author":"Soltan","year":"2017","journal-title":"BMJ"},{"key":"2025121605195859000_14.8.e082553.18","unstructured":"NSW Ministry of Health . NSW clinical guidelines: treatment of opioid dependence 2018. North Sydney NSW: NSW Ministry of Health, 2018."},{"key":"2025121605195859000_14.8.e082553.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-017-2031-8","article-title":"Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework","volume":"17","author":"Sekhon","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"2025121605195859000_14.8.e082553.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-022-01245-0","article-title":"The updated consolidated framework for implementation research based on user feedback","volume":"17","author":"Damschroder","year":"2022","journal-title":"Implement Sci"},{"key":"2025121605195859000_14.8.e082553.21","unstructured":"Sobell L , Sobell M , Buchan G . Timeline followback method (drugs, cigarettes, and marijuana). Fort Lauderdale, FL: Center for Psychological Studies Nova Southeastern University, 1996."},{"key":"2025121605195859000_14.8.e082553.22","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.2.184"},{"key":"2025121605195859000_14.8.e082553.23","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4679(197710)33:4<981::AID-JCLP2270330412>3.0.CO;2-0"},{"key":"2025121605195859000_14.8.e082553.24","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1007\/s11136-016-1337-z","article-title":"Deriving population norms for the aqol-6D and aqol-8D multi-attribute utility instruments from web-based data","volume":"25","author":"Maxwell","year":"2016","journal-title":"Qual Life Res"},{"key":"2025121605195859000_14.8.e082553.25","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12083"},{"key":"2025121605195859000_14.8.e082553.26","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/add.15331","article-title":"Assessing the concurrent validity, inter-rater reliability and test-re-test reliability of the australian treatment outcomes profile (ATOP) in alcohol and opioid treatment populations","volume":"116","author":"Deacon","year":"2021","journal-title":"Addiction"},{"key":"2025121605195859000_14.8.e082553.27","unstructured":"Government. TGADoHaACA . Note for guidance on clinical safety data management: definitinos and standards for expedited reporting (CPMP\/ICH\/377\/95), 2000. Available: https:\/\/www.tga.gov.au\/resources\/publication\/publications\/note-guidance-clinical-safety-data-management-definitions-and-standards-expedited-reporting"},{"key":"2025121605195859000_14.8.e082553.28","doi-asserted-by":"publisher","DOI":"10.1002\/nur.20247"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-082553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:20:10Z","timestamp":1765891210000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-082553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,3]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/bmjopen-2023-082553"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-082553","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}